41445-88-9

Basic information

• Product Name: Z-Val-OCO₂ⁱBu
• Synonyms: Z-Val-OCO₂ⁱBu
• CAS NO: 41445-88-9
• Molecular Weight: 351.4
• Mol File: 41445-88-9.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Z-Val-OCO₂ⁱBu(CAS DataBase Reference)
• NIST Chemistry Reference: Z-Val-OCO₂ⁱBu(41445-88-9)
• EPA Substance Registry System: Z-Val-OCO₂ⁱBu(41445-88-9)

Safety Data

• Hazardous Substances Data: 41445-88-9(Hazardous Substances Data)

Upstream product

• 1685-33-2 N-[(benzyloxy)carbonyl]-D-valine 
• 543-27-1 isobutyl chloroformate 
• 501-53-1 benzyl chloroformate 
• 640-68-6 D-Val-OH 
• 72-18-4 L-valine 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 

Downstream Products

• 159949-02-7 [(S)-2-Methyl-1-(3,3,3-trifluoro-2-hydroxy-1-phenethyl-propylcarbamoyl)-propyl]-carbamic acid benzyl ester 
• 1115-74-8 Val-Ala 
• 3918-94-3 Val-Val 
• 3918-92-1 L-valyl L-phenylalanine 
• 1258214-10-6 benzyl [(3R)-1-bromo-4-methyl-2-oxopentan-3-yl]carbamate 
• 1258214-09-3 benzyl [(1R)-1-(2-{5-bromo-2-[(ethylcarbamoyl)amino]pyridin-4-yl}-1,3-thiazol-4-yl)-2-methylpropyl]carbamate 
• 1258214-04-8 6-(4-(4-((R)-1-(benzyloxycarbonylamino)-2-methylpropyl)thiazol-2-yl)-6-(3-ethylureido)pyridin-3-yl)-1-((S)-1-hydroxy-3,3-dimethylbutan-2-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 184296-03-5 (S)-2-{(R)-2-[(S)-2-((S)-2-Benzyloxycarbonylamino-3-methyl-butyrylamino)-3-(tert-butyl-dimethyl-silanyloxy)-propionylamino]-3-phenyl-propionylamino}-3-(tert-butyl-dimethyl-silanyloxy)-propionic acid methyl ester 
• 128647-47-2 Z-D-Val-NHMe 
• 128647-50-7 N-benzyloxycarbonyl-L-valine methylamide 
• 117507-21-8 Z-Val-Val-Ala-Ala-OMe 
• 117507-31-0 Z-Ala-Val-Val-Ala-Ala-pNA 
• 117507-18-3 Z-Val-Val-Ala-Ala-pNA 
• 117507-25-2 Z-Val-Val-Ala-pNA 

Relevant articles and documents

Lewis acid- and cationic lithium-mediated diastereoselective aldol-type reaction based on a double chiral recognition manner for the asymmetric synthesis of α-substituted serines

Diastereoselective aldol-type reaction of ethyl (5R or 5S)-3,6-diethoxy-2,5-dihydro-5-isopropyl-2-pyrazinecarboxylate (5) with chiral aldehyde 7 was investigated by using Sn(OSO2CF3)2-N-ethylpiperizine, MgBr2-Et

HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF

Compounds of formula (IA) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

Preparation and structure-activity relationship of novel P1/P1'- substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors

A series of novel P1/P1'-substituted cyclic urea-based HIV-1 protease inhibitors was prepared. Three different synthetic schemes were used to assemble these compounds. The first approach uses amino acid-based starting materials and was originally used to prepare DMP 323. The other two approaches use L-tartaric acid or L-mannitol as the starting material. The required four contiguous R,S,S,R centers of the cyclic urea scaffold are introduced using substrate control methodology. Each approach has specific advantages based on the desired P1/P1' substituent. Designing analogs based on the enzyme's natural substrates provided compounds with reduced activity. Attempts at exploiting hydrogen bond sites in the S1/S1' pocket, suggested by molecular modeling studies, were not fruitful. Several analogs had better binding affinity compared to our initial leads. Modulating the compound's physical properties led to a 10-fold improvement in translation resulting in better overall antiviral activity.